Why Are Biogen Shares Gaining Today?_老虎社区_美港股上老虎

Why Are Biogen Shares Gaining Today?

Benzinga2021-11-12

Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease. The analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

100

Troytan
·2021-11-14
Well done
回复
1
举报
ch888
·2021-11-13
ok
回复
点赞
举报
RocketToMars
·2021-11-13
Ok
回复
1
举报
Nana_seven
·2021-11-12
Like pls o
回复
1
举报
收起
- char_liew:
  Ok
  2021-11-13
  回复
  举报
JANICELSJ
·2021-11-12
Like please
回复
2
举报
收起
- SKLow:
  pls like,tq
  2021-11-12
  回复
  举报
- Nana_seven:
  Ok
  2021-11-12
  回复
  举报
PanaCota
·2021-11-12
Ok
回复
2
举报
收起
- halforc:
  yes
  2021-11-12
  回复
  举报
jovrene
·2021-11-12
Hmmmn
回复
3
举报
收起
- Anniet:
  lol
  2021-11-12
  回复
  举报
BBBBBBBBBB
·2021-11-12
Ok
回复
3
举报
JovRene
·2021-11-12
Hmmmn
回复
4
举报
收起
- Excelsheet:
  Ok
  2021-11-12
  回复
  举报
- Jojo888:
  Ok
  2021-11-12
  回复
  举报
Olympous
·2021-11-12
Ok
回复
4
举报
收起
- JovRene:
  ok
  2021-11-12
  回复
  举报
Jimmyboy
·2021-11-12
Please like
回复
7
举报
收起
- SKLow:
  pls like,tq
  2021-11-12
  回复
  举报
- Olympous:
  ok
  2021-11-12
  回复
  举报
- Cfgramos:
  Okd
  2021-11-12
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1152324783?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-12 21:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152324783","market":"us","top_or_hot":-1,"title":"Why Are Biogen Shares Gaining Today?","media":"Benzinga","content":"<div>\n<p>Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today\">网页链接</a>\n\n</div>\n","source":"lsy1606299360108","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Biogen Shares Gaining Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Biogen Shares Gaining Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today","article_id":"1152324783","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152324783","pubTimestamp":1636724821,"sourceInfo":{"source_id":"lsy1606299360108","name":"Benzinga"},"weMediaInfo":null,"summary":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's dise","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司"},"translate_title":"为什么生物原股票今天会上涨？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":0.9},"content_text":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.\nAccording to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.\nBiogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.\nThe Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.\nIn one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.\nIn the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.\nPrice Action: BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":873931643,"gmtCreate":1636822966143,"gmtModify":1636822966303,"author":{"id":"3571482048865852","authorId":"3571482048865852","name":"Troytan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Well done","listText":"Well done","text":"Well done","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873931643","repostId":1152324783,"repostType":4,"repost":{"id":"1152324783","pubTimestamp":1636724821,"share":"https://www.laohu8.com/m/news/1152324783?lang=&edition=full","pubTime":"2021-11-12 21:47","market":"us","language":"en","title":"Why Are Biogen Shares Gaining Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152324783","media":"Benzinga","summary":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's dise","content":"<ul>\n <li><b>Biogen Inc</b>&nbsp;and&nbsp;<b>Eisai Co Ltd</b>&nbsp;have&nbsp;new data released&nbsp;for Aduhelm (aducanumab-avwa) in Alzheimer's disease.</li>\n <li>The analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.</li>\n <li>According to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.</li>\n <li>Biogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.</li>\n <li>The Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.</li>\n <li>In one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.</li>\n <li>In the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.</li>\n <li><b>Price Action:</b>&nbsp;BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Biogen Shares Gaining Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Biogen Shares Gaining Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152324783","content_text":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.\nAccording to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.\nBiogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.\nThe Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.\nIn one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.\nIn the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.\nPrice Action: BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":879522034,"gmtCreate":1636750958578,"gmtModify":1636750958578,"author":{"id":"3581804654549595","authorId":"3581804654549595","name":"ch888","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879522034","repostId":1152324783,"repostType":4,"repost":{"id":"1152324783","pubTimestamp":1636724821,"share":"https://www.laohu8.com/m/news/1152324783?lang=&edition=full","pubTime":"2021-11-12 21:47","market":"us","language":"en","title":"Why Are Biogen Shares Gaining Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152324783","media":"Benzinga","summary":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's dise","content":"<ul>\n <li><b>Biogen Inc</b>&nbsp;and&nbsp;<b>Eisai Co Ltd</b>&nbsp;have&nbsp;new data released&nbsp;for Aduhelm (aducanumab-avwa) in Alzheimer's disease.</li>\n <li>The analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.</li>\n <li>According to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.</li>\n <li>Biogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.</li>\n <li>The Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.</li>\n <li>In one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.</li>\n <li>In the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.</li>\n <li><b>Price Action:</b>&nbsp;BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Biogen Shares Gaining Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Biogen Shares Gaining Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152324783","content_text":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.\nAccording to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.\nBiogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.\nThe Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.\nIn one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.\nIn the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.\nPrice Action: BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":879584405,"gmtCreate":1636738936047,"gmtModify":1636738936194,"author":{"id":"3549455086460474","authorId":"3549455086460474","name":"RocketToMars","avatar":"https://static.tigerbbs.com/e454fc8aa9e282f1caae6fe919b0b36e","vip":1,"crmLevel":7,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879584405","repostId":1152324783,"repostType":4,"repost":{"id":"1152324783","pubTimestamp":1636724821,"share":"https://www.laohu8.com/m/news/1152324783?lang=&edition=full","pubTime":"2021-11-12 21:47","market":"us","language":"en","title":"Why Are Biogen Shares Gaining Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152324783","media":"Benzinga","summary":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's dise","content":"<ul>\n <li><b>Biogen Inc</b>&nbsp;and&nbsp;<b>Eisai Co Ltd</b>&nbsp;have&nbsp;new data released&nbsp;for Aduhelm (aducanumab-avwa) in Alzheimer's disease.</li>\n <li>The analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.</li>\n <li>According to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.</li>\n <li>Biogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.</li>\n <li>The Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.</li>\n <li>In one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.</li>\n <li>In the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.</li>\n <li><b>Price Action:</b>&nbsp;BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Biogen Shares Gaining Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Biogen Shares Gaining Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152324783","content_text":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.\nAccording to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.\nBiogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.\nThe Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.\nIn one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.\nIn the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.\nPrice Action: BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":879299831,"gmtCreate":1636725956825,"gmtModify":1636725956939,"author":{"id":"3575673754947065","authorId":"3575673754947065","name":"Nana_seven","avatar":"https://static.tigerbbs.com/cbfa864cf0a3b766b4090b0ad3b67e69","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Like pls o","listText":"Like pls o","text":"Like pls o","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879299831","repostId":1152324783,"repostType":4,"repost":{"id":"1152324783","pubTimestamp":1636724821,"share":"https://www.laohu8.com/m/news/1152324783?lang=&edition=full","pubTime":"2021-11-12 21:47","market":"us","language":"en","title":"Why Are Biogen Shares Gaining Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152324783","media":"Benzinga","summary":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's dise","content":"<ul>\n <li><b>Biogen Inc</b>&nbsp;and&nbsp;<b>Eisai Co Ltd</b>&nbsp;have&nbsp;new data released&nbsp;for Aduhelm (aducanumab-avwa) in Alzheimer's disease.</li>\n <li>The analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.</li>\n <li>According to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.</li>\n <li>Biogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.</li>\n <li>The Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.</li>\n <li>In one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.</li>\n <li>In the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.</li>\n <li><b>Price Action:</b>&nbsp;BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Biogen Shares Gaining Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Biogen Shares Gaining Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152324783","content_text":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.\nAccording to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.\nBiogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.\nThe Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.\nIn one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.\nIn the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.\nPrice Action: BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6557801,"gmtCreate":1636767852428,"gmtModify":1636767852458,"authorId":3584923882881298,"author":{"id":3584923882881298,"authorId":3584923882881298,"name":"char_liew","avatar":"https://static.tigerbbs.com/8aecba864f5e9a00425071f07c5d1794","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":879299831,"type":1,"supId":0,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"}],"langContent":"CN"},{"id":879207707,"gmtCreate":1636725795176,"gmtModify":1636725795318,"author":{"id":"3579777216498074","authorId":"3579777216498074","name":"JANICELSJ","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Like please&nbsp;","listText":"Like please&nbsp;","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/879207707","repostId":1152324783,"repostType":4,"repost":{"id":"1152324783","pubTimestamp":1636724821,"share":"https://www.laohu8.com/m/news/1152324783?lang=&edition=full","pubTime":"2021-11-12 21:47","market":"us","language":"en","title":"Why Are Biogen Shares Gaining Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152324783","media":"Benzinga","summary":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's dise","content":"<ul>\n <li><b>Biogen Inc</b>&nbsp;and&nbsp;<b>Eisai Co Ltd</b>&nbsp;have&nbsp;new data released&nbsp;for Aduhelm (aducanumab-avwa) in Alzheimer's disease.</li>\n <li>The analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.</li>\n <li>According to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.</li>\n <li>Biogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.</li>\n <li>The Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.</li>\n <li>In one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.</li>\n <li>In the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.</li>\n <li><b>Price Action:</b>&nbsp;BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Biogen Shares Gaining Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Biogen Shares Gaining Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152324783","content_text":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.\nAccording to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.\nBiogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.\nThe Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.\nIn one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.\nIn the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.\nPrice Action: BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6551893,"gmtCreate":1636727109166,"gmtModify":1636727109258,"authorId":3582927789816025,"author":{"id":3582927789816025,"authorId":3582927789816025,"name":"SKLow","avatar":"https://static.tigerbbs.com/b3aeaabd2ee1ec9afcdda5a4aab1994c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":879207707,"type":1,"supId":0,"prevId":0,"content":"pls like,<u>tq</u>","text":"pls like,<u>tq</u>","html":"pls like,<u>tq</u>"},{"id":6551666,"gmtCreate":1636725950568,"gmtModify":1636725950667,"authorId":3575673754947065,"author":{"id":3575673754947065,"authorId":3575673754947065,"name":"Nana_seven","avatar":"https://static.tigerbbs.com/cbfa864cf0a3b766b4090b0ad3b67e69","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":879207707,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":879202521,"gmtCreate":1636725573502,"gmtModify":1636725573740,"author":{"id":"3581588474178431","authorId":"3581588474178431","name":"PanaCota","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879202521","repostId":1152324783,"repostType":4,"repost":{"id":"1152324783","pubTimestamp":1636724821,"share":"https://www.laohu8.com/m/news/1152324783?lang=&edition=full","pubTime":"2021-11-12 21:47","market":"us","language":"en","title":"Why Are Biogen Shares Gaining Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152324783","media":"Benzinga","summary":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's dise","content":"<ul>\n <li><b>Biogen Inc</b>&nbsp;and&nbsp;<b>Eisai Co Ltd</b>&nbsp;have&nbsp;new data released&nbsp;for Aduhelm (aducanumab-avwa) in Alzheimer's disease.</li>\n <li>The analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.</li>\n <li>According to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.</li>\n <li>Biogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.</li>\n <li>The Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.</li>\n <li>In one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.</li>\n <li>In the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.</li>\n <li><b>Price Action:</b>&nbsp;BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Biogen Shares Gaining Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Biogen Shares Gaining Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152324783","content_text":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.\nAccording to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.\nBiogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.\nThe Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.\nIn one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.\nIn the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.\nPrice Action: BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6551593,"gmtCreate":1636725590303,"gmtModify":1636725590340,"authorId":3573464435831021,"author":{"id":3573464435831021,"authorId":3573464435831021,"name":"halforc","avatar":"https://static.tigerbbs.com/231f5e9ec930fe4701bdb16cb6485b9a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":879202521,"type":1,"supId":0,"prevId":0,"content":"<u>yes</u>","text":"<u>yes</u>","html":"<u>yes</u>"}],"langContent":"CN"},{"id":879208039,"gmtCreate":1636725388076,"gmtModify":1636725388217,"author":{"id":"4095592624574210","authorId":"4095592624574210","name":"jovrene","avatar":"https://static.tigerbbs.com/a068b755584903947da2a9b01a9599de","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Hmmmn","listText":"Hmmmn","text":"Hmmmn","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879208039","repostId":1152324783,"repostType":4,"repost":{"id":"1152324783","pubTimestamp":1636724821,"share":"https://www.laohu8.com/m/news/1152324783?lang=&edition=full","pubTime":"2021-11-12 21:47","market":"us","language":"en","title":"Why Are Biogen Shares Gaining Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152324783","media":"Benzinga","summary":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's dise","content":"<ul>\n <li><b>Biogen Inc</b>&nbsp;and&nbsp;<b>Eisai Co Ltd</b>&nbsp;have&nbsp;new data released&nbsp;for Aduhelm (aducanumab-avwa) in Alzheimer's disease.</li>\n <li>The analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.</li>\n <li>According to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.</li>\n <li>Biogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.</li>\n <li>The Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.</li>\n <li>In one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.</li>\n <li>In the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.</li>\n <li><b>Price Action:</b>&nbsp;BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Biogen Shares Gaining Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Biogen Shares Gaining Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152324783","content_text":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.\nAccording to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.\nBiogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.\nThe Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.\nIn one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.\nIn the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.\nPrice Action: BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6551596,"gmtCreate":1636725625792,"gmtModify":1636725625887,"authorId":3579570110340350,"author":{"id":3579570110340350,"authorId":3579570110340350,"name":"Anniet","avatar":"https://static.tigerbbs.com/3f443f29823834bbea85dd67baf5dfda","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":879208039,"type":1,"supId":0,"prevId":0,"content":"<u>lol</u>","text":"<u>lol</u>","html":"<u>lol</u>"}],"langContent":"CN"},{"id":879201578,"gmtCreate":1636725373118,"gmtModify":1636725373333,"author":{"id":"3581562365927542","authorId":"3581562365927542","name":"BBBBBBBBBB","avatar":"https://static.tigerbbs.com/973395458d7e1db24dbd4a689c79e8a2","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879201578","repostId":1152324783,"repostType":4,"repost":{"id":"1152324783","pubTimestamp":1636724821,"share":"https://www.laohu8.com/m/news/1152324783?lang=&edition=full","pubTime":"2021-11-12 21:47","market":"us","language":"en","title":"Why Are Biogen Shares Gaining Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152324783","media":"Benzinga","summary":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's dise","content":"<ul>\n <li><b>Biogen Inc</b>&nbsp;and&nbsp;<b>Eisai Co Ltd</b>&nbsp;have&nbsp;new data released&nbsp;for Aduhelm (aducanumab-avwa) in Alzheimer's disease.</li>\n <li>The analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.</li>\n <li>According to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.</li>\n <li>Biogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.</li>\n <li>The Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.</li>\n <li>In one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.</li>\n <li>In the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.</li>\n <li><b>Price Action:</b>&nbsp;BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Biogen Shares Gaining Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Biogen Shares Gaining Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152324783","content_text":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.\nAccording to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.\nBiogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.\nThe Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.\nIn one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.\nIn the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.\nPrice Action: BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":879209630,"gmtCreate":1636725166004,"gmtModify":1636725209501,"author":{"id":"4095072535386190","authorId":"4095072535386190","name":"JovRene","avatar":"https://static.tigerbbs.com/cc1c4680fc5d92b0cbb4f5ea0eadaa83","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Hmmmn","listText":"Hmmmn","text":"Hmmmn","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/879209630","repostId":1152324783,"repostType":4,"repost":{"id":"1152324783","pubTimestamp":1636724821,"share":"https://www.laohu8.com/m/news/1152324783?lang=&edition=full","pubTime":"2021-11-12 21:47","market":"us","language":"en","title":"Why Are Biogen Shares Gaining Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152324783","media":"Benzinga","summary":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's dise","content":"<ul>\n <li><b>Biogen Inc</b>&nbsp;and&nbsp;<b>Eisai Co Ltd</b>&nbsp;have&nbsp;new data released&nbsp;for Aduhelm (aducanumab-avwa) in Alzheimer's disease.</li>\n <li>The analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.</li>\n <li>According to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.</li>\n <li>Biogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.</li>\n <li>The Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.</li>\n <li>In one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.</li>\n <li>In the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.</li>\n <li><b>Price Action:</b>&nbsp;BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Biogen Shares Gaining Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Biogen Shares Gaining Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152324783","content_text":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.\nAccording to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.\nBiogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.\nThe Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.\nIn one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.\nIn the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.\nPrice Action: BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6551520,"gmtCreate":1636725293374,"gmtModify":1636725293468,"authorId":3563191428086420,"author":{"id":3563191428086420,"authorId":3563191428086420,"name":"Excelsheet","avatar":"https://static.tigerbbs.com/30a30f253a4cec57f0a4d67ec91c7847","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":879209630,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6551517,"gmtCreate":1636725287817,"gmtModify":1636725287853,"authorId":3583107816650694,"author":{"id":3583107816650694,"authorId":3583107816650694,"name":"Jojo888","avatar":"https://static.tigerbbs.com/2f316062a27488f432a277a1f87465cc","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":879209630,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":879200790,"gmtCreate":1636725112450,"gmtModify":1636725112533,"author":{"id":"3580732020483404","authorId":"3580732020483404","name":"Olympous","avatar":"https://static.tigerbbs.com/3a8af001d967b1e9c67ad207e8390558","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879200790","repostId":1152324783,"repostType":4,"repost":{"id":"1152324783","pubTimestamp":1636724821,"share":"https://www.laohu8.com/m/news/1152324783?lang=&edition=full","pubTime":"2021-11-12 21:47","market":"us","language":"en","title":"Why Are Biogen Shares Gaining Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152324783","media":"Benzinga","summary":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's dise","content":"<ul>\n <li><b>Biogen Inc</b>&nbsp;and&nbsp;<b>Eisai Co Ltd</b>&nbsp;have&nbsp;new data released&nbsp;for Aduhelm (aducanumab-avwa) in Alzheimer's disease.</li>\n <li>The analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.</li>\n <li>According to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.</li>\n <li>Biogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.</li>\n <li>The Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.</li>\n <li>In one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.</li>\n <li>In the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.</li>\n <li><b>Price Action:</b>&nbsp;BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Biogen Shares Gaining Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Biogen Shares Gaining Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152324783","content_text":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.\nAccording to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.\nBiogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.\nThe Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.\nIn one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.\nIn the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.\nPrice Action: BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6551489,"gmtCreate":1636725177916,"gmtModify":1636725177987,"authorId":4095072535386190,"author":{"id":4095072535386190,"authorId":4095072535386190,"name":"JovRene","avatar":"https://static.tigerbbs.com/cc1c4680fc5d92b0cbb4f5ea0eadaa83","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":879200790,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":879200330,"gmtCreate":1636725051672,"gmtModify":1636725051836,"author":{"id":"3582072891665879","authorId":"3582072891665879","name":"Jimmyboy","avatar":"https://static.tigerbbs.com/cb9d5d497bceb3edaca216e9eeab3c22","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/879200330","repostId":1152324783,"repostType":4,"repost":{"id":"1152324783","pubTimestamp":1636724821,"share":"https://www.laohu8.com/m/news/1152324783?lang=&edition=full","pubTime":"2021-11-12 21:47","market":"us","language":"en","title":"Why Are Biogen Shares Gaining Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152324783","media":"Benzinga","summary":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's dise","content":"<ul>\n <li><b>Biogen Inc</b>&nbsp;and&nbsp;<b>Eisai Co Ltd</b>&nbsp;have&nbsp;new data released&nbsp;for Aduhelm (aducanumab-avwa) in Alzheimer's disease.</li>\n <li>The analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.</li>\n <li>According to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.</li>\n <li>Biogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.</li>\n <li>The Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.</li>\n <li>In one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.</li>\n <li>In the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.</li>\n <li><b>Price Action:</b>&nbsp;BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Biogen Shares Gaining Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Biogen Shares Gaining Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152324783","content_text":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.\nAccording to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.\nBiogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.\nThe Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.\nIn one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.\nIn the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.\nPrice Action: BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6551905,"gmtCreate":1636727156680,"gmtModify":1636727156789,"authorId":3582927789816025,"author":{"id":3582927789816025,"authorId":3582927789816025,"name":"SKLow","avatar":"https://static.tigerbbs.com/b3aeaabd2ee1ec9afcdda5a4aab1994c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":879200330,"type":1,"supId":0,"prevId":0,"content":"pls like,<u>tq</u>","text":"pls like,<u>tq</u>","html":"pls like,<u>tq</u>"},{"id":6551481,"gmtCreate":1636725090960,"gmtModify":1636725090996,"authorId":3580732020483404,"author":{"id":3580732020483404,"authorId":3580732020483404,"name":"Olympous","avatar":"https://static.tigerbbs.com/3a8af001d967b1e9c67ad207e8390558","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":879200330,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":6551476,"gmtCreate":1636725066172,"gmtModify":1636725066271,"authorId":3577318628836449,"author":{"id":3577318628836449,"authorId":3577318628836449,"name":"Cfgramos","avatar":"https://static.tigerbbs.com/8e4f5dee285970cb0d50c61a4302a33f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":879200330,"type":1,"supId":0,"prevId":0,"content":"Okd","text":"Okd","html":"Okd"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":100,"commentSize":11,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}